

NHMA PRESENTS

ZOOM WEBINAR - SESSION 3

Biomarker Testing: Improving Access to Improve Care

Moderator



**Elena Rios, MD,
MSPH, MACP**
President and CEO
National Hispanic
Medical Association



Speaker

Estelamari Rodriguez, MD, MPH

Associate Director of Community Outreach and Co-Lead of
the Thoracic Site Disease Group
Sylvester Comprehensive Cancer Center at the University of Miami Miller School of Medicine

Dr. Rodriguez is board certified in medical oncology and hematology. She has a special interest in the early detection of lung cancer and developing programs to eradicate healthcare disparities.



August 25th, 2022

12-1:00 p.m ET



Welcome

Elena Rios, MD, MSPH, MACP

President & CEO

National Hispanic Medical Association

Housekeeping

- All participant microphones will be muted, but please feel free to use the raised hand feature to be unmuted to ask a question or type your question into the Q & A box for the panelists to address during our Q & A session at the end.
- The recording will be housed on NHMAmd.org and our YouTube channel.
- The recording and slides will be sent out one week after the event.

Supported by **AMGEN**

NHMA
National Hispanic Medical Association

Agenda & Learning Objectives

Agenda

- Overview of Biomarker Testing presentation – Dr. Estelamari Rodriguez, MD, MPH
- Legislative Discussion – Hilary Gee Goeckner, MSW Senior State and Local Campaign Manager ACS CAN – Access to Care
- Roundtable Discussion with patient Julia Maues
- Q & A from Audience

Learning Objectives

- To educate health advocates about biomarker testing among Hispanics with cancer.
- To discuss policies that are potential Texas State solutions to barriers of biomarker testing

The Importance of Biomarker Testing for the Hispanic/LatinX Community

Estelamari Rodriguez, MD, MPH
Thoracic Oncologist
Co-Lead Thoracic Site Disease Group
Associate Director Community Outreach



A Cancer Center Designated by the
National Cancer Institute

Cancer Mortality Among Hispanics

Leading Causes of Mortality for Hispanics: 1) Cancer

Leading Causes Mortality for NHWs:

1) Heart Disease


2) Heart Disease

2) Cancer

3) Accidents

3) COPD

Incidence



Estimated Deaths

Males			Females		
Lung & bronchus	3,500	16%	Breast	3,200	16%
Liver & intrahepatic bile duct	2,700	12%	Lung & bronchus	2,600	13%
Colon & rectum	2,400	11%	Colon & rectum	1,800	9%
Prostate	2,000	9%	Pancreas	1,600	8%
Pancreas	1,700	8%	Liver & intrahepatic bile duct	1,300	6%
Stomach	1,100	5%	Ovary	1,100	5%
Leukemia	1,000	5%	Uterine corpus	1,000	5%
Non-Hodgkin lymphoma	1,000	4%	Leukemia	900	4%
Kidney & renal pelvis	900	4%	Stomach	800	4%
Brain & other nervous system	700	3%	Non-Hodgkin lymphoma	700	3%
All sites	22,300	100%	All sites	20,400	100%

Lung Cancer: Racial and Ethnic Disparities


Latinos with lung cancer:

16% less likely to be diagnosed early

Equally likely to receive surgical treatment

26% more likely to not receive any treatment,

16% less likely to survive five years compared to white Americans.



What is Biomarker Testing? Why Is it Important?

Biomarker Testing



Biomarker Testing is any molecule that can be measured in your blood, tumor tissue, or other bodily fluids to help inform treatment decisions.




Comprehensive biomarker testing can help your healthcare team identify your appropriate treatment options. Guidelines recommend Broad Molecular Testing at the time of diagnosis of advanced/ recurrent lung cancer.



Genomics and Biomarker Testing have revolutionized the discovery and investigation of novel drug targets/ targeted therapies

35% of Patients With Advanced Nonsq NSCLC Have a Driver Mutation Targetable by an FDA-Approved Agent



*Approved in combination with trametinib (MEK inhibitor) for BRAF V600E mutation.

The Power of Targeted Therapy




6 FEB 2002



11 FEB 2002

Biomarker Testing Drives Discovery Drug Approvals In Lung Cancer



May 2020:

- Ramucirumab + Erlotinib
- Nivolumab + Ipi
- Brigatinib (1st line)
- Atezolizumab-(PDL1High)
- Capmatinib
- Selpercatinib

June 2020:

- Lurbinectedin

Sept 2020:

- Praselitinib

Feb 2021:

- Tepotinib
- Cemiplimab

May 2021:

- Sotorasib (KrasG12c)
- Amivantamab (EGFR Ex20)

Sept 2021:

- Mobocertinib (EGFREx20)

Barriers to Access for Biomarker Testing

Guideline-Recommended Biomarker Testing May Improve Patients Outcomes

Adherence to testing for guideline-recommended biomarkers, regardless of therapy

Decreased mortality risk by **11%**

*This was a retrospective study of 28,784 patients diagnosed with advanced NSCLC. Adherence to biomarker testing consisted of patients with evidence of testing for any biomarker, including *EGFR*, *ALK*, *BRAF*, *KRAS*, *ROS1*, or *PD-L1* between 14 days prior to and 90 days after diagnosis of advanced NSCLC and the main outcome, overall survival (OS), was agnostic to treatment.¹⁰

†Multivariable analysis was adjusted for age at diagnosis of advanced NSCLC, sex, smoking status, and stage at initial diagnosis of NSCLC.¹⁰

Many Patients With Newly Diagnosed NSCLC Do Not Receive Broad Molecular Testing¹¹



~ **50%**
of metastatic patients
received comprehensive
biomarker testing^{11,‡}

Regardless of patient characteristics such as age, race, and smoking status, **biomarker testing** should be conducted in **all eligible patients** with advanced NSCLC¹²

¹¹A retrospective, observational study assessing real-world biomarker testing patterns in 3,474 patients with metastatic NSCLC from community oncology practices within The US Oncology Network between 2018 and 2020.¹¹

Racial disparities in biomarker testing and clinical trial enrollment

Real World Practice Cohort (Flatiron)
N=14,768 Stage IV NSCLC
Diagnosed 1/2017-10/2020
Treated within 120 days of diagnosis

- Black patients less likely to get NGS
- **Participation in clinical trials lower** in patients without biomarker testing




Biomarker Testing

All patients with NSCLC				
	NSCLC overall N=14,768	White N=9,793	Black/AA N=1,288	P-value, White vs Black/AA
Ever tested	11,297 (76.5%)	7477 (76.4%)	948 (73.6%)	0.03
Tested prior to first line therapy		6,064 (61.9%)	784 (60.9%)	0.47
Ever NGS tested	7,185 (48.7%)	4,904 (50.1%)	513 (39.8%)	<0.0001
NGS tested prior to first line therapy		3,081 (31.5%)	332 (25.8%)	<0.0001
Patients with non-squamous NSCLC				
	Non-squamous N=10,333	White N=6,705	Black/AA N=922	P-value, White vs Black/AA
Ever tested	8,786 (85.0%)	5,699 (85.0%)	764 (82.9%)	0.09
Tested prior to first line therapy		4,881 (72.8%)	662 (71.8%)	0.52
Ever NGS tested	5,494 (53.2%)	3,668 (54.7%)	404 (43.8%)	<0.0001
NGS tested prior to first line therapy		2,452 (36.6%)	274 (29.7%)	<0.0001

AA = African American; NGS = next-generation sequencing

Barriers to Biomarker Testing in the Hispanic Population



Thank You

@latinamd

estelarodriguez@miami.edu



A Cancer Center Designated by the
National Cancer Institute

Legislative and Advocacy Overview

Biomarker Testing


Hilary Gee Goeckner, MSW

*Senior State and Local Campaigns Manager – Access to Care
American Cancer Society Cancer Action Network*



Barriers to Cancer Biomarker Testing

Steps to Biomarker-Driven Targeted Cancer Therapy to Improve Patient Outcomes




Legislation to Address Coverage

Biomarker testing must be covered for the purposes of diagnosis, treatment, appropriate management, or ongoing monitoring of an enrollee's disease or condition when the test is supported by medical and scientific evidence, including, but not limited to:

- 1. Labeled indications for an FDA-approved or -cleared test or indicated tests for an FDA-approved drug;*
- 2. Centers for Medicare and Medicaid Services (CMS) National Coverage Determinations and Medicare Administrative Contractor (MAC) Local Coverage Determinations; or*
- 3. Nationally recognized clinical practice guidelines and consensus statements.*

Legislation to Expand Access to Biomarker Testing



Legislation introduced: CA, MN, NY, OH, WA

Legislation passed: AZ, IL, LA, RI



fightcancer.org/biomarkers





Roundtable Discussion



Audience Q & A

NHMA Upcoming Events

- **COVID-19 Virtual Briefing Session 17, August 31, 2022 7 – 8:15PM ET**
 - Register here: <https://bit.ly/covidsession17>
- **NHMA Southern California Chapter Event – September 9, 2022 6-9:00 PM PT ET**
 - University of Southern California Caruso Catholic Center in Los Angeles, CA
 - RSVP by Friday, September 2nd
 - <https://bit.ly/nhmasocal>
- **NHMA HIV Chapter Forum – September 14, 2022 1-2:00 PM ET**
 - Register here: <https://bit.ly/HIVCF2022>
- **NHMA 26th Annual Conference:** Chicago, IL – April 27 – April 30th, 2023: Hyatt Regency Chicago
- **NHMA VaccinateForAll Campaign**
 - New websites launched – [HispanicHealth.info](https://www.hispanichealth.info) & [Vaccinateforall.org](https://www.vaccinateforall.org)
 - Register for FREE to join over 200+ individuals and organizations the champions today!



If you have any questions about our programs or events, please email vgearity@nhmamd.org or jhernandez@nhmamd.org

Thank You



[facebook.com/
NHMAmd.org](https://facebook.com/NHMAmd.org)



[@NHMAmd](https://www.instagram.com/@NHMAmd)



[bit.ly/
NHMALinkedIn](https://bit.ly/NHMALinkedIn)



[@NHMAmd](https://www.twitter.com/@NHMAmd)



[NHMA@
NHMAmd.org](mailto:NHMA@NHMAmd.org)